Kornimate/medical-research-clean huggingface dataset:
pragmatic airway resuscitation trial

Conditions: Cardiac Arrest

Summary: the primary objective of the trial is to determine if 72-hour survival after out-of-hospital cardiac arrest (ohca) is improved with initial endotracheal intubation (eti) over initial laryngeal tube (lt) airway management strategies.

the primary objective of the trial is to determine if 72-hour survival after out-of-hospital cardiac arrest (ohca) is improved with initial endotracheal intubation (eti) over initial laryngeal tube (lt) airway management strategies. the null hypothesis is that 72-hour survival is similar between primary laryngeal tube (lt) sga and primary eti airway management strategies. evaluated secondary outcomes will include return of spontaneous circulation, survival to hospital discharge, neurologically intact survival at hospital discharge, airway management performance, and clinical adverse events.

Eligibility criteria:
inclusion criteria: * out-of-hospital cardiac arrest (ohca) * adult (age ≥18 years or per local interpretation) * non-traumatic etiology * initiation of ventilatory support (e.g., bag-valve-mask device, non-rebreather mas, etc.) exclusion criteria: * known pregnant women * known prisoners * major facial trauma (visible major deformity, copious oral bleeding, etc) * major bleeding or exsanguination (e.g., major upper or lower gi bleed, visceral perforation, major uncontrolled bleeding from laceration or injury) * patient receiving initial care by a non-part participating ems agency capable of performing eti, lt, or other advanced airway management * patients with et tube, lt or other advanced airway device inserted prior to participating ems agency arrival (e.g., inserted by healthcare facility personnel) * patients with a pre-existing tracheostomy * obvious asphyxial cardiac arrest (e.g., choking, foreign body aspiration, angioedema, epiglottitis, trauma to mouth and face, etc.) * patients with a left ventricular assist device (lvad) or total artificial heart (tah) * patients with pre-existing written "do-not-attempt-resuscitation" (dnar) orders * inter-facility transports * patients with a "do not enroll" bracelet

Keywords: cardiac arrest cardiopulmonary resuscitation laryngeal tube endotracheal intubation non-traumatic out of hospital cardiac arrest (oohca)
the utility of thromboelastography in cirrhotic patients undergoing endoscopic procedures

Conditions: Cirrhosis, Coagulopathy

Summary: cirrhosis results in decreased synthesis of both procoagulants and anticoagulants resulting in "rebalanced homeostasis". however, conventional blood tests (platelets/ inr levels) that are performed prior to invasive procedures do not accurately reflect the coagulation changes that occur in cirrhotics, resulting in unnecessary transfusion of blood products. thromboelastography (teg) is a global hemostasis assessment tool that is being used in surgery (including liver transplant) to help guide blood product transfusion in the operating room. the investigators would like to compare the use of teg vs. inr/platelets to help guide blood product transfusion in cirrhotic patients undergoing inpatient endoscopy. the investigators will evaluate to see if there is a decrease in prophylactic blood transfusions prior to endoscopy when using teg.


Eligibility criteria:
inclusion criteria: * all 18 yo + cirrhotic patients who are being scheduled for inpatient endoscopy exclusion criteria: * patients on blood thinners (prophylactic anticoagulation is permissible) * hemodynamically unstable patients requiring pressors (ie icu level patients) * pregnant or lactating individuals * inability to provide consent for any reason
study to evaluate the effect of bydureon on 24-hour glucose control in metformin treated patients with type 2 diabetes.

Conditions: Type 2 Diabetes

Summary: a randomized, double-blind, parallel-group study to evaluate the effect of bydureon compared with placebo on 24-hour glucose control in metformin-treated patients with type 2 diabetes.

a randomized, double-blind, parallel-group study to evaluate the effect of bydureon compared with placebo on 24-hour glucose control in 110 metformin-treated patients with type 2 diabetes

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus (t2dm) treated with stable dose of metformin \> or = to 1500mg/day as monotherapy for at least 8 weeks * hemoglobin a1c (hba1c) 7% to 10% at screening * body mass index (bmi) \< or = to 45 kg/m2 exclusion criteria: * history of taking antihyperglycemic therapy other than metformin or metformin extended release (xr) during the 8 weeks prior to screening * history of taking a dipeptidyl peptidase-4 (dpp-4) inhibitor or pramlintide during 12 weeks prior to screening * history of potent, inhaled or intrapulmonary steroids 3 months prior to screening or during the study * history of prescription or over the counter weight loss medication during 3 months prior to screening * previous exposure to exenatide or any glucagon-like peptide-1 (glp-1) receptor agonist during 6 months prior to screening
gastric bypass and peripheral activity of the endocannabinoid system

Conditions: Obesity

Summary: the aim of the study is to precise the effect of a large amount of weight loss induced by gastric bypass on the endocannabinoid system (plasma and adipose tissue) of morbidly obese patients and to determine the influence of a gastric bypass surgery compared to a lifestyle intervention with equivalent weight loss on the endocannabinoid system

dysregulation of the endocannabinoid system has been associated with the development of obesity, metabolic and cardiovascular disorders in both animals and humans. obese patients, especially those with abdominal obesity, have significantly higher levels of endocannabinoids. no influence of moderate (5%) body weight loss (induced either by diet intervention or sibutramine) on the peripheral activity of the endocannabinoid system gastric bypass (gb) surgery is the most efficient treatment of obesity hormonal pathways may participate to the weight reducing effect of the procedure.the endocannabinoid system is present in the gastrointestinal tract. in animals, sustained weight loss after gb is characterized by reduction of endocannabinoids levels. the endocannabinoid levels will be studied (baseline and after stimulation) in: * normal-weight subjects * obese subjects before and after gastric bypass surgery * obese subjects before and after a lifestyle intervention

Eligibility criteria:
inclusion criteria: * arms 1 and 2: * age between 18 and 60 * bmi \> 40kg/m² or at least 30kg/m² with complication * medical follow up before surgery * patients that engaged themselves to a long medical follow up * efficient contraception * written, informed consent of each subject before the beginning of the study * arm 3: * age between 18 and 60 * bmi between 18 and 25 kg/m² * stable weight over the 3 past months * restrain score \ 4 at the tfeq * no job in the endocrinology department * written, informed consent of each subject before the beginning of the study exclusion criteria: * arms 1,2 and 3 * no care of obesity before inclusion * incapacity of the patient to follow a medical follow up * drug or alcohol abuse * urine test result positive for thc * threaten life diseases * pregnancy, breast feeding * smoking

Keywords: morbid obesity bariatric surgery lifestyle intervention endocannabinoids system
bupivacaine with dexmedetomidine versus bupivacaine alone for transversus abdominis plane block in caesarean section

Conditions: Post Operative Pain

Summary: transversus abdominis plane (tap) block is a regional technique for providing analgesia of the anterolateral abdominal wall. tap block are commonly given in patients who have undergone various abdominal as well as pelvic surgeries such as caesarean section, hysterectomy, appendicectomy and various laparoscopic surgeries. this study is conducted to analyse the effect of addition of dexmedetomidine to bupivacaine in transversus abdominis plane (tap) block.

peripheral nerve block is becoming increasingly popular technique for postoperative pain relief and is also established as a part of multimodal analgesia and enhanced recovery program. transversus abdominis plane (tap) block is a regional technique for providing analgesia of the anterolateral abdominal wall. tap block are commonly given in patients who have undergone various abdominal as well as pelvic surgeries such as caesarean section, hysterectomy, appendicectomy and various laparoscopic surgeries.the purpose of a tap block is to infiltrate local anaesthetic agents in the plane between the internal oblique and transversus abdominis muscles thereby providing effective postoperative analgesia. earlier the blind tap block (through lumbar triangle of petit) was commonly given but with widespread use of ultrasound nowadays it is almost always given under ultrasound guidance. accuracy and efficacy of tap block is significantly improved under ultrasound guidance because under ultrasound guidance the anesthetic agent can be properly deposited in the neurovascular plane. ultrasound provides real time and direct visualisation of needle during infiltration of local anaesthetic drug.

Eligibility criteria:
inclusion criteria: * pregnant female elected for cesarean section * asall exclusion criteria: * coagulopathy * bmi\>35 * heart diseases * diabets
clopidogrel resistance and platelet reactivity in women undergoing percutaneous coronary intervention

Conditions: Acute Coronary Syndrome; Coronary Artery Disease

Summary: plavix (clopidogrel) is a drug that is approved by the fda (food and drug administration) to reduce the risk of having another heart attack by preventing platelets (blood cells that are important in forming blood clots) from sticking together and forming another clot. platelet activity can be measured by a machine called verifynow. the purpose of this study is to see whether hispanic women and white non-hispanic women have the same platelet response to a commonly used drug, plavix (clopidogrel). recent studies have shown that platelets may be more active in hispanics, making it more difficult to prevent clots from forming, even when using plavix. in addition, studies have shown that women may also have more active platelets than men. there have been no studies of hispanic women and the effect of plavix on platelet activity.


Eligibility criteria:
inclusion criteria: * all females age 45 or greater, presenting to university of arizona medical center south campus or university campus cardiology service with a history of acs * hispanics will be defined via self-reporting as having both parents of latino descent * currently taking clopidogrel exclusion criteria: * taking any of the following antiplatelet drugs: * prasugrel (effient) * ticagrelor (brilinta) * ticlopidine (ticlid)

Keywords: female hispanic percutaneous coronary intervention
effect of 4 liver fibrosis tests (piiinp, civ, ln, and ha) on the prognosis of liver cirrhosis

Conditions: Liver Cirrhosis

Summary: liver biopsy is the reference method for the measurement of liver fibrosis. but it has many limitations, such as sampling error and individual variation in interpreting the results. currently, serum liver fibrosis markers have been employed as non-invasive diagnosis of liver fibrosis and evaluation of the severity of liver fibrosis. they include laminin (ln), hyaluronic acid (ha), collagen type iv (civ), and n-terminal propeptide of collagen iii (piiinp). however, few study was conducted to explore the role of these liver fibrosis markers in evaluating the prognosis of liver cirrhosis. our hypothesis is that ln, ha, civ, and piiinp in combination or alone can predict the prognosis of liver cirrhosis.


Eligibility criteria:
inclusion criteria: 1. patients were admitted to our department. 2. patients were diagnosed with liver cirrhosis. 3. patients signed the informed consent and agreed to test serum liver fibrosis markers (piiinp, civ, ln, and ha). exclusion criteria: 1. non-cirrhotic patients. 2. malignancy. 3. severe cardiopulmonary diseases. 4. severe infectious diseases. 5. other diseases with a shortened lifespan. 6. pregnant and breastfeeding. 7. poor adherence.

Keywords: prognosis
study evaluating a heated lidocaine and tetracaine topical patch in the treatment of patients with patellar tendinopathy

Conditions: Patellar Tendinopathy

Summary: the purpose of the study is to explore the potential usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with patellar tendinopathy.

the purpose of this pilot study is to explore the potential usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with patellar tendinopathy. a number of efficacy variables will be employed to evaluate their utility for assessing painful responses in this population. the study will be a 2-week, open-label study conducted at a single study site in patients with pain associated with patellar tendinopathy in a single knee. during this out-patient study, patients will apply one study patch to the affected tendon twice daily for approximately 14 days. patches will be applied morning and evening (applications separated by approximately 8-10 hours) and removed after 2-4 hours.

Eligibility criteria:
inclusion criteria: * be at least 18 years of age * have pain associated with patellar tendinopathy in a single knee (minimum 2-week duration) * have tenderness at the proximal insertion of the patellar tendon in the affected knee exclusion criteria: * have any history of surgery in the target knee * have used any topically applied pain medication on the target treatment area within 3 days preceding the screening/baseline visit * have had any injected steroids in the target knee within 3 months of the screening/baseline visit * have used any injected pain medication within 14 days preceding the screening/baseline visit * are receiving class 1 antiarrhythmic drugs (ie, tocainide, mexiletine, etc.) other protocol-defined inclusion/exclusion criteria may apply.

Keywords: patellar tendonitis
safety and efficacy of low dosage of terazosin in subjects undergoing carotid artery stenting

Conditions: Carotid Artery Stenosis

Summary: the purpose of this study is to assess the safety and efficacy of low dosage of terazosin in carotid artery stenting


Eligibility criteria:
inclusion criteria: 1. symptomatic or asymptomatic carotid artery stenosis. in symptomatic patients the degree of stenosis should more than 50% (based on nascet criteria), in asymptomatic patients the degree of stenosis should more than 70% (based on nascet criteria); 2. tolerance to any of the study medications, including tz, clopidogrel, aspirin and statins; 3. hypertensive patients with or without oral antihypertensive drugs 4. can cooperate with and complete brain mri examination; 5. stable vital signs, cardiopulmonary, liver and kidney function was no obvious abnormalities; 6. has a negative pregnancy test within 7 days before randomization and no childbearing potential; 7. stable vital sign, normal renal and hepatic functions; 8. informed consent. exclusion criteria: 1. evolving stroke; 2. hemorrhagic tendency； 3. severe dementia or prior major ipsilateral stroke, if likely to confound study endpoints; 4. chronic atrial fibrillation or any other cardiogenic emboli source disease; 5. myocardial infarction within previous 30 days; 6. spontaneous intracerebral hemorrhage within the past 180 days, hemorrhagic conversion of an ischemic stroke within the past 60 days or recent (\<7 days) large area cerebral infarction has a hemorrhagic conversion tendence; 7. any conditions that hampers proper angiographic assessment or makes percutaneous arterial access unsafe; 8. high risk candidates of cas defined as the carotid revascularization endarterectomy vs. stenting trial (crest); 9. thiazides taken within 14 days before randomization; 10. participating in any other clinical trial that has not completed the required protocol follow-up period;

Keywords: carotid artery stenting silent embolism terazosin
innovating a questionnaire to investigate the awareness of dermatologists regarding the role of physical therapy

Conditions: Measure the Level of Awareness of Dermatologists

Summary: the purpose of this study will be developing a questionnaire to evaluate the level of awareness of dermatologists regarding the role of physical therapy in patients with different skin diseases. background: skin diseases encompass a wide range of conditions that affect the skin, hair, and nails. they can be acute or chronic, benign or malignant, and can significantly impact an individual's quality of life. understanding the epidemiology, causes, types, prevalence, and treatment options of skin diseases is crucial for effective management and improving patient outcomes, especially in regions like the middle east and egypt. the treatment of skin diseases in the middle east and egypt involves a combination of topical and systemic therapies, lifestyle modifications, and sometimes surgical interventions. while treatments can be effective, they may also have side effects physical therapy plays a significant and often underappreciated role in the management of various skin diseases. while traditionally associated with musculoskeletal and neurological conditions, it can also be beneficial in treating and managing skin-related disorders


Eligibility criteria:
inclusion criteria: * dermatologists that will be included in the study will be with; 1. professional status: must be a certified dermatologist. 2. location: must be practicing in cairo teaching hospitals. 3. active practice: must currently be practicing either in a clinical setting, hospital, or private practice. 4. consent: must provide informed consent to participate in the study. 5. experience: dermatologists of more than 5 years of experience. exclusion criteria: * this study will exclude dermatologists with the following criteria; 1. non-dermatologists: professionals who are not dermatologists, such as general practitioners, nurses, or other healthcare providers who do not specialize in dermatology. 2. inactive professionals: dermatologists who are retired or currently not practicing for any reason (e.g., on extended leave). 3. non-consenting individuals: individuals who do not agree to participate in the study or who do not provide informed consent. 4. incomplete surveys: participants who do not complete the entire survey or interview process, depending on the data collection method used in the study. 5. non-egyptian practitioners: dermatologists practicing outside of egypt, even if they are egyptian nationals, to maintain a focus on the practices and awareness within the egyptian healthcare system

Keywords: physical therapy dermatologists skin diseases referral practices interprofessional collaboration awareness egypt questionnaire
effect of clinical and biochemical variables over morbidity and mortality in alcohol withdrawal syndrome patients

Conditions: Alcohol Withdrawal Syndrome

Summary: the goal of this observational study is to describe the impact measured through the odds ratio (or) of different variables of clinical and biochemical alterations on the duration of the syndrome alcohol withdrawal patients measured in days of symptoms and stay; it could include any patients with a diagnosis of admission of alcohol withdrawal syndrome (aws) who have been treated in the department of internal medicine for 5 years. the main question it aims to answer is: what is the relationship between the different clinical, biochemical, and hematic factors on the duration of symptoms, morbidity, and mortality in individuals with alcohol syndrome withdrawal? • if the patient has a greater number of risk factors, such as advanced age, a long and chronic history of alcohol consumption, the type of distillate consumed, as well as the deterioration of liver function and presence of leukocytosis and neutrophilia, then it is postulated that the duration of alcohol withdrawal syndrome will be longer. clinical records will be used to describe the proportion of complications associated with alcohol withdrawal syndrome including pneumonia bronchial aspiration, seizures, need for mechanical ventilation, digestive tract hemorrhage, toxic-alcoholic hepatitis, and pancreatitis.

clinical records (files) of patients with a diagnosis of admission of alcohol withdrawal syndrome (aas) who have been treated in the department of internal medicine for 5 years.

Eligibility criteria:
inclusion criteria: * clinical records of patients, both genders, over 18 years of age with alcohol withdrawal syndrome according to the criteria for alcohol withdrawal. * clinical records of candidates for admission for neurological monitoring and with criteria for use of sedative drugs according to the ciwa-ar scale * clinical records of patients containing the ciwa-ar scale score at diagnosis exclusion criteria: * clinical records of patients who already have a history of seizures or epilepsy * clinical records of diabetic patients with diabetic ketoacidosis * clinical records of patients who have not received any type of sedative treatment * clinical records of patients with chronic liver failure or liver cirrhosis * clinical records of patients with chronic liver disease with signs of hepatic encephalopathy * clinical records of patients with related toxic-alcoholic hepatitis * clinical records of patients with a life expectancy of less than 24 hours due to associated complications such as head trauma or other associated complications * clinical records of patients who require intubation and mechanical ventilation upon admission * clinical records of patients who have a vascular event that modifies the neurological evaluation * clinical records of patients who before admission show psychomotor alteration or neurological deterioration that modifies the neurological evaluation such as the presence of wernicke's encephalopathy